নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

gedeon richter plc - levonorgestrel - intrauterint innlegg - 20 mikrog/24 timer

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

bayer ab - solna - levonorgestrel - intrauterint innlegg - 20 mikrog/24 timer

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lavet pharmaceuticals ltd. - prazikvantel / pyrantelembonat / febantel - tyggetablett - 175 mg / 504 mg / 525 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lavet pharmaceuticals ltd. - prazikvantel / pyrantelembonat / febantel - tyggetablett - 50 mg / 144 mg / 150 mg

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - repaglinid - diabetes mellitus, type 2 - legemidler som brukes i diabetes - repaglinid er indisert hos pasienter med type 2 diabetes (ikke-insulinavhengig diabetes mellitus (niddm)) hvis hyperglykemi ikke lenger kan kontrolleres tilfredsstillende ved diett, vektreduksjon og trening. behandling bør initieres som et tillegg til diett og trening for å senke blodsukkeret i forhold til måltider.

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

ferring legemidler as - dinoproston - vaginalinnlegg - 10 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

pascoe pharmazeutische präparate gmbh - askorbinsyre - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 150 mg/ ml

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - alle andre terapeutiske produkter - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofunginacetat - candidiasis; aspergillosis - antimykotika for systemisk bruk - behandling av invasiv candidiasis i voksen eller paediatric pasienter. behandling av invasive aspergillosis i voksen eller paediatric pasienter som er refraktære til eller intolerante av amfotericin b, lipid formuleringer av amfotericin b og/eller itrakonazol. refraktivitet er definert som progresjon av infeksjon eller unnlatelse av å forbedre etter minimum 7 dager før terapeutiske doser av effektive soppdrepende behandling. empirisk behandling for antatte fungal infeksjoner (for eksempel candida eller aspergillus) i febrile, neutropaenic voksen eller paediatric pasienter.